<DOC>
	<DOCNO>NCT01171417</DOCNO>
	<brief_summary>For patient receive Faslodex 500 mg , compare effectiveness term Time Progression ( TTP ) function line treatment ( i.e . 1st vs. 2nd vs. 3rd line ) . For patient , collect explore real-life data epidemiology management Pseudomyxoma Peritonea ( PMP ) patient HR+ advance breast cancer ( ABC ) treat Faslodex 500 mg exemestane .</brief_summary>
	<brief_title>A Treatment With Fulvestrant Exemestane Postmenopausal Patients With Advanced Hormone Receptor-Positive ( HR ) + Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Signed write informed consent Female postmenopausal patient ( patient postovariectomy ) age ≥18 year Postmenopause ist define Age ≥ 60 year natural menopause menses &gt; 1year ago FSH E2 level postmenopausal range Patients bilateral ovariectomy ( NCCN V.I . 2009 ) Histologically confirm ER+ locally advance metastatic breast cancer Not eligible curative therapy Prior treatment tamoxifen Suitable undergo endocrine treatment ER+ ABC SERD / sAI Patient able read understand German Known hypersensitivity Faslodex Exemestane compound drug Prior treatment Faslodex 500 mg Faslodex 250 mg* patient receive treatment Faslodex 500 mg within observational study . Patients include exemestane arm may receive prior Faslodex treatment . Prior treatment Exemestane patient receive treatment Exemestane within observational study Acutely life threaten disease Treatment Faslodex 250 mg/month ( previously approve dose ) Prior palliative chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Fulvestrant</keyword>
	<keyword>Exemestane</keyword>
	<keyword>postmenopausal patient</keyword>
	<keyword>advanced HR+ breast cancer</keyword>
	<keyword>Hormone Receptor positive</keyword>
	<keyword>advanced breast cancer</keyword>
</DOC>